论文部分内容阅读
加人WTO对中国来讲是一件大好事,但是对众多医药中小企业来说,却不尽然。与国外医药巨头相比,我国的国有大型医药企业,尚且如航母面前的小舢板,更何况实力有限的中小企业。为研究中国医药企业顺利进入WTO的143个国家关税区共同大市场,寻找更多的国际合作伙伴,由中国中药协会、中国非处方药物协会、中国民族医药学会联合举办WTO——中国医药企业总裁新年国际论坛暨国际经贸洽谈会。 本届论坛主题为:WTO——中国医药企业的全球化发展;埃及、南非、印度、摩洛哥、丹麦等30个国家的驻华大使、
Joining the WTO is a good thing for China, but it is not always true for many small and medium-sized medical companies. Compared with foreign pharmaceutical giants, China’s state-owned large-scale pharmaceutical enterprises are still small plates in front of their aircraft carriers, not to mention the limited small and medium-sized enterprises. In order to study the successful entry of Chinese pharmaceutical companies into the common market of 143 countries in the WTO, look for more international partners by the China Association of Chinese Pharmacopoeia, China OTC Pharmaceutical Association and China National Institute of Ethnology International Forum and International Trade Fair. The theme of this forum is: WTO - the globalization of Chinese pharmaceutical companies; ambassadors to 30 countries including Egypt, South Africa, India, Morocco and Denmark;